Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma

Status:
Completed

Trial end date:
2020-09-25

Target enrollment:

Participant gender:

Patients will be enrolled in two stages: - Dose-escalation stage: Approximately 12-24 patients will be enrolled.

Phase 1

Genexine, Inc.